Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactofiltrum + metronidazole
- Development stage
- Unknown
- Lead developer
- Avva Rus
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical, Vaginal, Intravenous
01
Overview
Lactofiltrum + metronidazole is a combination of two agents used in clinical practice. Metronidazole is a nitroimidazole-class antibiotic and antiprotozoal agent that works by inhibiting nucleic acid synthesis in susceptible organisms through the formation of nitroso radicals that disrupt microbial DNA. It is primarily indicated for the treatment of anaerobic bacterial infections and certain protozoal infections such as trichomoniasis and amebiasis[1][2][3][6][7]. Lactofiltrum is an over-the-counter enterosorbent containing lignin hydrolyzed and lactulose; it acts as an intestinal adsorbent to bind toxins and metabolites in the gut but does not have direct antimicrobial activity. The combination may be used off-label to manage gastrointestinal disorders where both infection (treated by metronidazole) and toxin adsorption (by lactofiltrum) are desired.
- Brand names
- MetrocreamMetrolotionNidagelNoritateNuvessaPyleraRosadanVandazole
- Other names
- lactofiltrum + metronidazole
02
Targets
Neuraminidase
Beyond the preview
Go deeper on lactofiltrum + metronidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactofiltrum + metronidazole.